Veradermics, Incorporated

Veradermics, Incorporated FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Veradermics, Incorporated (MANE) as of Oct 19, 2026 is 102.33 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 89.43 % — a change of 14.43% (higher).

FCF Conversion

102.33 %

YoY

14.43%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Veradermics, Incorporated is 2025 102.33 % . FCF Conversion Rate (FCF/EBITDA) of Veradermics, Incorporated was 2024 89.43 % . It decreases by 14.43% higher compared to the previous year.

The Veradermics, Incorporated FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2023
81.93 USD
Jan 1, 2024
89.43 USD
Jan 1, 2025
102.33 USD
The Veradermics, Incorporated FCF Conversion history
YEARFCF ConversionYoY
102.33 %+14.43%
89.43 %+9.16%
81.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Veradermics, Incorporated Stock analysis

What does Veradermics, Incorporated do? Veradermics, Incorporated is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut. The company focuses on developing novel therapeutics for dermatologic and aesthetic conditions. Veradermics is developing treatments for pattern hair loss affecting adults and children. The company's product pipeline includes VDPHL01, an oral, non-hormonal treatment for pattern hair loss. It is also developing VDMN, a dissolvable microarray patch technology for immunotherapy of common warts, VDAA for the treatment of alopecia areata, and VDMC for the treatment of molluscum contagiosum. Veradermics' products target conditions including androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers, clinicians, and the broader medical and clinical research community involved in dermatology, treating both adult and pediatric populations. Veradermics, Incorporated has an IPO date of February 4, 2026, and its ticker symbol is MANE. The company's website is https://www.veradermics.com. The company is incorporated in the United States and operates under the ISIN US9229671048. The sector and industry classifications for Veradermics are currently unknown. Veradermics, Incorporated is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veradermics, Incorporated stock

FCF Conversion Rate (FCF/EBITDA) of Veradermics, Incorporated is 102.33 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Veradermics, Incorporated changed from 89.43 % to 102.33 %, representing a 14.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Veradermics, Incorporated since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Veradermics, Incorporated with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Veradermics, Incorporated

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Veradermics, Incorporated